Autres langues Valerio Therapeutics

Actions

ALVIO

FR0010095596

Produits pharmaceutiques

Temps réel Euronext Paris Autres places de cotation 09:40:01 04/08/2026			Varia. 5j.	Varia. 1 janv.
0,7310 ^EUR	-1,75%		-2,14%	+429,71%

16/07	Valerio Therapeutics conclut un accord de principe avec Abivax en R&D
16/07	Valerio Therapeutics et Abivax concluent une collaboration de R&D dans les thérapies contre les maladies inflammatoires	MT

Autres langues

16/07	Valerio Therapeutics, Abivax Enter R&D Collaboration for Inflammatory Disease Therapies
16/07	Valerio Therapeutics, Abivax Sign R&D Deal for Inflammatory Diseases' Drug Candidates
16/07	Valerio Therapeutics Enters into Binding Term-Sheet with Abivax for Exclusive Global Research and Development Collaboration and Provides Pipeline Update
16/07	Valerio Therapeutics Announces Development Collaboration with Abivax and Provides Pipeline Update
16/07	Valerio Therapeutics : Announces Development Collaboration with Abivax and Provides Pipeline Update
01/07	Valerio Therapeutics Announces Binding Offer for the Proposed Acquisition of Etherna Immunotherapies, Creating a Global Leader in Targeted RNA Medicines
01/07	Valerio Therapeutics : announces binding offer for the proposed acquisition of Etherna Immunotherapies, creating a global leader in targeted RNA medicines
01/07	Valerio Therapeutics Société anonyme signed a letter of intent to acquire eTheRNA immunotherapies NV for an enterprise value of ?30 million.
17/06	Valerio Therapeutics Names New CEO
16/06	Valerio Therapeutics Appoints Gilles Besin as Chief Executive Officer and Announces Results of its Annual General Meeting
16/06	Valerio Therapeutics Société Anonyme Announces Board and Executive Changes
16/06	Valerio Therapeutics Société Anonyme Announces CEO Changes
16/06	Valerio Therapeutics : Appoints Gilles Besin as Chief Executive Officer and Announces Results of its Annual General Meeting
19/05	Valerio Therapeutics Signs Binding Term-sheet for V-Body Platform Collaboration
18/05	Valerio Therapeutics enters into collaboration & exclusive license with seed-stage biotech co
18/05	Valerio Therapeutics Announces Binding Term-Sheet for Collaboration and Exclusive License With Seed-Stage Biotech Company
18/05	Valerio Therapeutics Enters Binding Term-Sheet for Collaboration and Exclusive License with Stealth-Mode Biotech Company
18/05	Valerio Therapeutics : announces binding term-sheet for collaboration and exclusive license with seed-stage biotech company
04/05	Valerio Therapeutics : Inside Information / Other news releases
04/05	Valerio Therapeutics Announces Launch of Invimmune and Provides Update on in Vivo Cell Therapy Approaches
04/05	Valerio Therapeutics Launches New Company for In Vivo Cell Therapies
04/05	Valerio Therapeutics Announces the Launch of InVimmune, a New Company Dedicated to Developing Differentiated in Vivo Cell Therapy Approaches
29/04	Valerio Therapeutics : Annual financial and audit reports / Terms of availability of the annual financial report
29/04	Valerio Therapeutics Publishes Its 2025 Annual Results and Annual Financial Report, and Confirms the Strategic Transformation of Its Operating Model
28/04	Valerio Therapeutics : publishes its 2025 annual results and annual financial report, and confirms the strategic transformation of its operating model